

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original) A stable pharmaceutical composition which comprises a pharmaceutical formulation with an amorphous active substance wherein the pharmaceutical formulation is packed into for gas exchange non-permeable package with packaging carried out in an inert gas atmosphere.

Claim 2. (original) The stable pharmaceutical composition according to Claim 1 wherein the amorphous active substance is atorvastatin calcium.

Claim 3. (original) The stable pharmaceutical composition according to Claim 1 wherein for gas exchange non-permeable package is Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.

Claim 4. (original) The stable pharmaceutical composition according to Claim 3 wherein for gas exchange non-permeable package is the Al/Al blister.

Claim 5. (original) The stable pharmaceutical composition according to Claim 1 wherein an inert gas is nitrogen or argon.

Claim 6. (original) The stable pharmaceutical composition according to Claim 5 wherein the inert gas is nitrogen.

Claim 7. (original) The stable pharmaceutical composition according to Claim 1 wherein the pharmaceutical composition is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.

Claim 8. (original) A stable pharmaceutical formulation comprising an amorphous active substance and pharmaceutically acceptable excipients which is stored in an inert atmosphere.

Claim 9. (original) The stable pharmaceutical formulation according to Claim 8 wherein the amorphous active substance is atorvastatin calcium.

Claim 10. (original) The stable pharmaceutical formulation according to Claim 8 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.

Claim 11. (original) The stable pharmaceutical formulation according to Claim 10 wherein the gas for maintenance of an inert atmosphere is nitrogen.

Claim 12. (original) The stable pharmaceutical formulation according to Claim 8 which is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.

Claim 13. (original) The stable pharmaceutical formulation according to Claim 8 which is stored into for gas non-permeable package such as Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.

Claim 14. (original) The stable pharmaceutical formulation according to Claim 13 wherein for gas non-permeable package is the Al/Al blister.

Claim 15. (original) A stable amorphous active substance which is stored in an inert atmosphere.

Claim 16. (original) The stable amorphous substance according to Claim 15 wherein the amorphous active substance is atorvastatin calcium.

Claim 17. (original) The stable amorphous active substance according to Claim 15 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.

Claim 18. (original) The stable amorphous active substance, according to Claim 15 wherein the gas for maintenance of an inert atmosphere is nitrogen.

Claim 19. (original) The stable amorphous active substance, according to Claim 15 wherein the active substance is stored into for gas exchange non-permeable packaging such as a metal container, glass container, for gas non-permeable plastic bag or for gas non-permeable plastic container.

Claim 20. (original) The stable amorphous active substance according to Claim 19 wherein for the exchange non-permeable packaging is the plastic bag.

Claim 21. (original) A method of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with the amorphous active substance wherein the pharmaceutical formulation is packed into for gas exchange non-permeable packaging and the packaging procedure is carried out in an inert gas atmosphere.

Claim 22. (original) The method of stabilization of the pharmaceutical composition according to Claim 21 wherein the amorphous active substance is atorvastatin calcium.

Claim 23. (original) The method of stabilization of the pharmaceutical composition according to Claim 21 wherein for gas exchange non-permeable packaging is Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.

Claim 24. (original) The method of stabilization of the pharmaceutical composition according to Claim 23 wherein for gas exchange non-permeable packaging is the Al/Al blister.

Claim 25. (original) The method of stabilization of the pharmaceutical composition according to Claim 21 wherein an inert gas is nitrogen or argon.

Claim 26. (original) The method of stabilization of the pharmaceutical composition according to Claim 25 wherein the inert gas is nitrogen.

Claim 27. (original) The method of stabilization of the pharmaceutical composition according to Claim 21 wherein the pharmaceutical formulation is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.

Claim 28. (original) A method of stabilization of a pharmaceutical formulation comprising an amorphous active substance and pharmaceutically acceptable excipients wherein a pharmaceutical formulation is stored in an inert atmosphere.

Claim 29. (original) The method of stabilization of the pharmaceutical formulation according to Claim 28 wherein the amorphous active substance is atorvastatin calcium.

Claim 30. (original) The method of stabilization of the pharmaceutical formulation according to Claim 28 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.

Claim 31. (original) The method of stabilization of the pharmaceutical formulation according to Claim 30 wherein the gas for maintenance of an inert atmosphere is nitrogen.

Claim 32. (original) The method of stabilization of the pharmaceutical formulation according to Claim 28 which is packed into for gas non-permeable packaging such as Al/Al blister, Al-polychloro-3-fluoroethylene homopolymer/PVC laminate blister or bottle.

Claim 33. (original) The method of stabilization of the pharmaceutical formulation according to Claim 32 wherein for gas non-permeable packaging is the Al/Al blister.

Claim 34. (original) The method of stabilization of the pharmaceutical formulation according to Claim 28 which is prepared in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pellets or granulate.

Claim 35. (original) A method of stabilization of an amorphous active substance wherein an amorphous substance is stored in an inert atmosphere.

Claim 36. (original) The method of stabilization of the amorphous active substance according to Claim 35 wherein the amorphous active substance is atorvastatin calcium.

Claim 37. (original) The method of stabilization of the amorphous active substance according to Claim 35 wherein the gas for maintenance of an inert atmosphere is nitrogen or argon.

Claim 38. (original) The method of stabilization of the amorphous active substance according to Claim 37 wherein the gas for maintenance of an inert atmosphere is nitrogen.

Claim 39. (original) The method of stabilization of the amorphous active substance according to Claim 35 wherein the active substance is packed into for gas non-permeable packaging such as metal container, glass container, for gas non-permeable plastic bag or for gas non-permeable plastic container.

Claim 40. (original) The method of stabilization of the amorphous active substance according to Claim 39 wherein for gas exchange non-permeable packaging is for gas non-permeable plastic bag.

Claim 41. (currently amended) The stable pharmaceutical composition comprising the pharmaceutical formulation with the amorphous active substance which is prepared by the process according to Claims 21 to 27.

Claim 42. (currently amended) The stable pharmaceutical formulation comprising the amorphous active substance and pharmaceutically acceptable excipients which is prepared by the process according to Claims 28 to 34.

Claim 43. (currently amended) The stable amorphous active substance which is prepared by the process according to Claims 35 to 40.

Claim 44. (original) The stable pharmaceutical composition according to Claim 1 is useful in treatment of hypercholesterolemia and hyperlipidemia.

Claim 45. (original) The stable pharmaceutical formulation according to Claim 8 is useful in the treatment of hypercholesterolemia and hyperlipidemia.

Claim 46. (original) The stable amorphous active substance according to Claim 15 is useful in the treatment of hypercholesterolemia and hyperlipidemia.